Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis

This is a phase III, multi-centre, double-blind, placebo-controlled, parallel group, nine-week study.

Both Hyper and Hypokalemic periodic paralysis patients were included.

Primary objective

Investigate the prevention of attacks of weakness.

This trial will be followed by 1-year extension without placebo. The extension will compare the long term effects of DCP on the course of the diseases and on inter-attack weakness.

Recruitment

42 patients were recruited.